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Abstract
The epigenome is a heritable layer of information 
not encoded in the DNA sequence of the genome, 
but in chemical modifications of DNA or histones. 
These chemical modifications, together with 
transcription factors, operate as spatiotemporal reg-
ulators of genome activity. Dissecting epigenome 
function requires controlled site-specific alteration 
of epigenetic information. Such control can be 
obtained using designed DNA-binding platforms 
associated with effector domains to function as tar-
geted transcription factors or epigenetic modifiers. 
Here, we review the use of dCas9 as a novel and 
versatile tool for fundamental studies on epigenetic 
landscapes, chromatin structure and transcription 
regulation, and the potential of this approach in 
basic research in these fields.
Introduction
The epigenome is a layer of information that, 
together with transcription factors, defines the cell-
type-specific gene expression pattern of a genome. 
By definition, epigenetic information is mitoti-
cally and/or meiotically heritable, but not directly 
encoded in the DNA sequence (Bird, 2007; Berger 
et al., 2009). Epigenetic information consists of 
covalent chemical modifications [post-translational 
modification of histone proteins that include, but 
are not limited to, methyl, acetyl, phosphoryl and 
ubiquitin groups (Turner, 2012) and methylation 
of cytosine bases (Vardimon et al., 1982; Schübeler, 
2015)] that alter the structure and physicochemi-
cal properties of DNA or DNA-bound histones 
(Bird, 2002; Kouzarides, 2007). Epigenetic modifi-
cation states are dynamic by nature and depend on 
enzymes transferring or removing these modifica-
tions (Holliday, 1987; Cubas et al., 1999; Chong 
and Whitelaw, 2004; Youngson and Whitelaw, 
2008). The epigenetic state of a genomic region 
is determined by combinations of modifications, 
but how exactly the resulting code is determined 
remains poorly understood (Gardner et al., 2011). 
These states correlate with gene expression and 
chromatin structure, and link the modification 
pattern of DNA and histones of genomic regions 
to states of development and differentiation (Hol-
liday, 2006; Henikoff and Shilatifard, 2011; Zhou 
et al., 2011; Turner, 2012; Smith and Meissner, 
2013).
A variety of diseases has been linked to muta-
tions in epigenetic maintenance enzymes or to 
misregulation of genes following aberrations in the 
epigenetic code (Kelly et al., 2010; Baylin and Jones, 
2011; Plass et al., 2013). Epigenome editing could 
develop into a tool used to revert aberrations in this 
code that lead to disease. Due to the lack of knowl-
edge of rare modifications and the combinatorics 
of DNA and histone modifications, it is unclear by 
what exact mechanisms epigenetic signals lead to 
downstream effects on gene regulation and chro-
matin conformation and whether as yet unknown 
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functional elements exist in genomes. To be able to 
provide answers to these questions, especially those 
on causality and the order of concerted processes, 
epigenetic effectors have been employed to study 
the implications of modification of the epigenome. 
Sequence-specific targeting of epigenetic modifiers 
has been instrumental in understanding the roles of 
epigenetic modifications on gene regulation. Here, 
we review current efforts aimed at manipulating the 
epigenome, focusing on the nuclease-deactivated 
Cas9 (dCas9) as versatile tool for sequence-specific 
recruitment of effector proteins.
Epigenome editing
Numerous studies have established correlations 
between epigenetic state and genome activity 
(Bernstein et al., 2010; Rivera and Ren, 2013; Road-
maps Epigenomics Consortium et al., 2015). 
Investigating the epigenome and establishing causal 
relationships rather than correlations will benefit 
from site-specific targeting of enzymes involved in 
establishing, disrupting and maintaining epigenetic 
states. Ideally, approaches to achieve this aim are 
readily adaptable to accommodate different target 
specificity and functionality.
The earliest efforts to edit epigenetic states and 
determine the effects of alterations therein involved 
gene knock-out or knock-down of specific epige-
netic modifiers (Stancheva and Meehan, 2000; 
Webster et al., 2005), or the use of compounds 
inhibiting the activity of these modifiers or their 
targets (Lyko and Brown, 2005). Such global strate-
gies, due to their pleiotropic impact, do not permit 
direct specific changes to be distinguished from 
secondary effects of the perturbation. Epigenetic 
modifiers – or their isolated functional domains 
– have been fused to DNA-binding proteins tar-
geted at specific loci. Zinc finger proteins (ZFPs), 
transcription activator-like effectors (TALEs) and 
nuclease-deactivated Cas9 (dCas9) have thus been 
employed successfully as tools for direct control 
of transcription, and – combined with a domain 
containing nuclease activity – for genome editing 
(Gaj et al., 2013). These DNA-binding proteins 
have also been used as vehicles to target epigenetic 
modifiers to specific loci. This application has been 
a major step forward in editing the epigenome (de 
Groote et al., 2012; Thakore et al., 2016). Below, we 
describe the three adaptable DNA-binding vehicles 
currently available for targeted recruitment of effec-
tors at designated genomic loci.
ZFPs
Zinc finger proteins (ZFPs) form a large class 
of DNA-binding proteins that use coordinated 
zinc ions to stabilize the typical ββα fold in their 
modular DNA-recognition domains. Each zinc 
finger domain consists of about 30 amino acids, 
capable of sequence-specific recognition of a 3–4 
base pair sequence (Pavletich and Pabo, 1991). 
The canonical zinc finger protein harbours three 
such domains. For increased target specificity, 
synthetic zinc finger proteins generally consist of 
4–6 zinc finger domains arranged in tandem. Choo 
et al. (1994) demonstrated in 1994 that it is pos-
sible to specifically target an oncogenic gene and 
reduce its transcription through transcriptional 
blockage by ZFP. This is the first instance of the 
use of a designed protein for manipulating gene 
expression at a defined locus. By targeting the 
histone methyltransferase (HMT) catalytic core 
using synthetic ZFPs to an endogenous genomic 
reporter system the causality of histone modifi-
cations in inducing repression of transcription 
was established (Snowden et al., 2002). Histone 
3 Lysine 9 methylation (H3K9me) was found 
to become enriched throughout a 500–1000 bp 
region around the target site. This spreading of 
the H3K9me mark, attributed to HP1, a protein 
associated with heterochromatin and mediator of 
gene silencing, resulted in repression of transcrip-
tion (Snowden et al., 2002). These applications of 
synthetic ZFPs are key examples of an adaptable 
DNA-binding platform tool, unique at the time, 
and laid the basis for the use of ZFP fusions in a 
wide range of applications (Klug, 2010; Urnov et 
al., 2010; Gersbach et al., 2014).
TALEs
Transcription activator-like effectors (TALEs) 
are DNA-binding proteins originating from plant 
pathogenic bacteria that consist of repeated motifs 
of 33 or 34 amino acids, with residues 12 and 13 
– so-called repeat variable di-residues (RVDs) 
– in each otherwise conserved repeat recogniz-
ing one particular base in double stranded DNA 
(Boch et al., 2009; Moscou and Bogdanove, 2009; 
Deng et al., 2012). TALE repeats can – by analogy 
with ZFPs – be designed in tandem to recognize 
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any DNA sequence of interest, with each repeat 
recognizing one base via its RVD (Zhang et al., 
2011; Mussolino and Cathomen, 2012). Since 
di-residues specific for each nucleotide have been 
identified, the rational design of DNA recognition 
is straightforward (Zhang et al., 2011; Reyon et al., 
2012). Nevertheless, target specificity of designed 
TALEs generally needs to be verified in vitro or 
in vivo (Morbitzer et al., 2010; Zhang et al., 2011; 
Grau et al., 2013; Guilinger et al., 2014). However, 
also TALEs and TALE–effector fusions verified 
to be target specific and active in a reporter assay 
may exhibit different activities when targeted at 
chromosomal sites, attributed to altered chromatin 
accessibility (Zhang et al., 2011). Although quite 
recently discovered, TALEs have proven their value 
next to ZFPs in gene expression modulation and 
genome editing (Sanjana et al., 2012; Gaj et al., 
2013). TALE fusions have also been used to target 
epigenetic modifiers to genomic loci. TALEs fused 
to the synthetic transactivation domain VP64 have 
been shown to up-regulate transcription of the 
endogenous pluripotency genes SOX2 and KLF4 in 
human 293FT cells, whereas TALE-VP64 targeted 
c-MYC and OCT4 genes were unaffected (Zhang et 
al., 2011). A TALE–TET1 fusion has been shown 
to decrease methylation of specific CpG dinucleo-
tides in the targeted promoter regions, resulting in 
increased mRNA expression levels of the targeted 
genes (Maeder et al., 2013a).
The use of both ZFPs and TALEs has been 
instrumental in achieving systematic and con-
trolled targeting of effectors to defined genomic 
loci. However, there are some drawbacks to the use 
of these DNA-binding proteins. The design of ZFPs 
to target specific DNA sequences is not as straight-
forward and modular as suggested above, as side 
chain–side chain interactions within and between 
adjacent zinc fingers complicate DNA recognition 
(Wolfe et al., 2000, 2001), precluding a robust 
‘recognition code’, permitting reliable engineer-
ing of highly specific DNA-recognition proteins. 
Although the DNA recognition via defined RVDs 
is more modular compared to ZFPs, TALE arrays 
also suffer from off-target binding (Guilinger et al., 
2014; Rogers et al., 2015). In fact, it has been shown 
that the protein context of a TALE repeat influences 
the DNA-binding specificity of the array (Rogers et 
al., 2015). A related drawback is that DNA binding 
of TALEs (Bultmann et al., 2012) and ZFPs (Choo, 
1998; Daniel et al., 2002; Vandevenne et al., 2013) 
is affected by the presence of methylated cytosines 
in target sequences, making application in genomic 
contexts more complicated and less flexible. Inde-
pendent of these drawbacks limiting application, 
it is important to realize that both tools require 
re-design of the protein sequence and validation 
for individual constructs targeting distinct DNA 
sequences. This process makes adaptation uncer-
tain as well as time and resource consuming. The 
capability of employing these proteins in multiplex 
or high-throughput screening applications is lim-
ited by this inflexibility of target adaptation.
dCas9
The CRIPSR-associated protein 9 (Cas9) is an 
antiviral enzyme of the Type II clustered regularly 
interspaced short palindromic repeat (CRISPR) 
adaptive immune system in prokaryotes (Barrangou 
et al., 2007; Bhaya et al., 2011). The endogenous 
enzyme introduces double-strand breaks in DNA 
using two catalytic domains (RuvC and HNH). 
Two RNA molecules – a CRISPR RNA (crRNA) 
and a trans-activating crRNA (tracrRNA) – are 
used to guide Cas9 to its target sequence. A proto-
spacer adjacent motif (PAM) flanking the target 
sequence recognized by the crRNA acts as an addi-
tional determinant in target recognition ( Jinek et 
al., 2012). In biotechnological applications the pro-
tein is generally guided by a chimeric single-guide 
RNA (sgRNA), a hybrid of crRNA and tracrRNA 
(Fig. 2.1).
Cas9 has been very rapidly and widely adopted 
(Doudna and Charpentier, 2014) as tool for 
genome editing (Cho et al., 2013a; Cong et al., 
2013; Hwang et al., 2013; Jinek et al., 2013; Mali 
et al., 2013b). The nuclease-deactivated variant, 
dCas9 (Fig. 2.1), initially created to establish which 
catalytic amino acids are necessary for dsDNA 
cleavage ( Jinek et al., 2012), laid the foundation 
for a whole range of new applications needing 
site-specific targeting. The dCas9 protein has been 
adopted as DNA-binding platform for applications 
as diverse as transcriptional blockage (Bikard et al., 
2013; Qi et al., 2013), gene expression modulation 
(Cheng et al., 2013; Gilbert et al., 2013), epigenetic 
editing (Hilton et al., 2015; Kearns et al., 2015) 
and staining of chromosomal regions for live cell 
imaging (Chen et al., 2013; Anton et al., 2014; Ma 
et al., 2015). In the next sections we discuss in detail 
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design strategies and applications of dCas9 for gene 
expression modulation and epigenetic editing.
dCas9 design strategies
Different strategies of varying complexity and 
efficacy for the use of dCas9 to manipulate the epig-
enome in controlled manner have been developed. 
In essence all these strategies belong to one of three 
categories discussed below (Fig. 2.2). Notably, 
some strategies discussed below have only been 
used for Cas9, but are equally suitable for use with 
dCas9.
Class I – direct effector fusion
In the most straightforward design, the dCas9 
protein (with no effector fused) is used to interfere 
with transcription via steric blockage of RNA poly-
merase binding or transcription elongation (Bikard 
et al., 2013; Qi et al., 2013). This strategy is success-
ful in prokaryotes leading up to ~300-fold mRNA 
reduction when a single sgRNA is used to target 
dCas9 or even ~1000-fold when two sgRNAs are 
combined to block transcription elongation (Qi et 
al., 2013). However, interference with transcrip-
tion has not been successful in mammalian cells 
yielding only ~2-fold reduction in transcript levels 
(Qi et al., 2013). For potent modulation of gene 
expression in mammalian cells by dCas9, specific 
effectors are implied. Down-regulation (CRIS-
PRi) or activation (CRISPRa) of targeted genes is 
achieved by genetically fusing effector proteins – or 
their active domains – to dCas9 and expressing 
them as a single recombinant protein (Fig. 2.2A). 
Transcription activator domains (VP64, p65) or 
repressor domains (KRAB, SID) have been fused 
to dCas9 to specifically increase or decrease target 
gene expression (Gilbert et al., 2013; Maeder et 
al., 2013b; Perez-Pinera et al., 2013; Lawhorn et 
al., 2014). Single dCas9–effector fusions are com-
monly targeted to adjacent sites using multiple 
different sgRNAs for maximum impact. In an effort 
to obtain maximum activation a combination of 
three different effectors (VP64, p65 and Rta) has 
been fused in succession to dCas9, resulting in a 
~100-fold increase in transactivation of the target 
genes compared to dCas9-VP64 alone (Chavez 
et al., 2015). A basic strategy towards achieving 
temporal control of dCas9–effector target binding 
is inducible expression of dCas9 or the sgRNA, e.g. 
by using a doxycycline (González et al., 2014; Wang 
et al., 2014; Dow et al., 2015) or IPTG-responsive 
promoter. However, this approach suffers from 
leaky expression in the absence of an inducer.
Class II – indirect effector recruitment
Class II strategies incorporate into the basic design 
additional motifs that recruit effector proteins (Fig. 
2.2B). An example of such a motif is the SunTag 
(Tanenbaum et al., 2014), a protein scaffold con-
taining peptide epitopes (a variant with 10 and one 
with 24 epitopes is available) able to recruit effector 
domains via specific single-chain variable fragment 
(scFv) antibodies (Fig. 2.2B). The SunTag-carrying 
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nuclease domains
Figure 2.1 The Cas9 endonuclease and its nuclease-deactivated variant dCas9. The CRISPR-associated protein 
9 (Cas9) is a prokaryotic antiviral protein that is guided by two RNA molecules (not shown) or, alternatively, one 
chimeric single-guide RNA (sgRNA) to cleave (using its RuvC and HNH catalytic domains) a target sequence 
containing a proper protospacer adjacent motif (PAM, in red) and matching the 20 nucleotide protospacer (in 
blue). Mutations in the nuclease domains (D10A and H840A in the commonly used Streptococcus pyogenes 
Cas9) result in a Cas9 variant, referred to as dCas9, capable of binding to the target sequence, but unable to 
cleave its target.
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Figure 2.2 Design strategies of using dCas9 to target effector domains to specific DNA sequences. (A) The 
effector domain is directly fused to dCas9 to recruit it to sequences specified by the sgRNA. (B) The effector 
domain(s) is recruited via functional scaffolds incorporated in the sgRNA–dCas9 complex, either via fusion to 
dCas9 (left) or via RNA aptamers in a scaffolding RNA (scRNA, right). (C) Spatiotemporal control of effector 
activity is obtained via controlled recruitment of effectors to the sgRNA–dCas9 complex (left) or the reconstitution 
of split-dCas9 directly fused to effectors (right) via light- or chemical-inducible heterodimerization partners.
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dCas9 has been shown to successfully recruit scFv–
VP64 fusions and to increase target gene expression 
more than the simple dCas9–VP64 fusion (Tanen-
baum et al., 2014).
More complex systems with added functionality 
are not limited to direct genetic fusion of effector 
domains to dCas9. The sgRNA can be extended to 
include RNA aptamers (Fig. 2.2B), secondary RNA 
structures specifically recognized by RNA-binding 
proteins, to form a scaffolding RNA (scRNA) (Mali 
et al., 2013a; Konermann et al., 2015; Zalatan et al., 
2015). Using scRNAs with RNA aptamers such 
as MS2, PP7, com or the PUF binding site (PBS), 
effectors can be recruited to the dCas9–sgRNA 
complex indirectly via fusion to corresponding 
RNA-binding proteins (Mali et al., 2013a; Zalatan 
et al., 2015; Cheng et al., 2016). Recruiting effec-
tors simultaneously via a dCas9 gene fusion and 
via aptamers present in the sgRNA has been shown 
to yield strong synergistic transactivation (Kon-
ermann et al., 2015; Xu et al., 2016). For example, 
recruiting two MS2–p65-HSF1 fusions to dCas9-
VP64 via an scRNA containing two MS2 hairpin 
aptamers resulted in a 100-fold enhancement of 
transactivation compared to just dCas9-VP64. 
Using just one scRNA this system outperformed 
a pool of eight sgRNAs targeting dCas9-VP64 to 
distinct sites along the proximal promoter region of 
target genes (Konermann et al., 2015).
Class III – spatiotemporal control of 
activity
In a third class, dCas9 strategies are aimed at pre-
cisely controlling effector recruitment or dCas9 
DNA-binding activity in space and/or time (Fig. 
2.2C). Such control has been achieved by using 
split-(d)Cas9 or split-(d)Cas9-effector proteins that 
are conditionally assembled into a functional DNA-
binding complex in the presence of sgRNA (Wright 
et al., 2015), upon chemical induction (Zetsche et 
al., 2015b) or light induction (Nihongaki et al., 
2015a). (d)Cas9, split in two individual domains, 
is assembled into a functional complex in the 
presence of full-length sgRNA. Truncated sgRNA 
prevents complex formation and can be used to 
disassemble the two Cas9 domains (Wright et al., 
2015). For chemical induction C- and N-terminal 
Cas9 (and dCas9) fragments have been fused to 
FK506 binding protein 12 (FKBP) and FKBP rapa-
mycin binding (FRB) domains, respectively, that 
dimerize upon rapamycin induction (Banaszynski 
et al., 2005; Zetsche et al., 2015b) (Fig. 2.2C). Using 
a split-dCas9 system fused to VP64, expression of 
target genes was shown to be specifically induced in 
the presence of rapamycin (Zetsche et al., 2015b). 
Another strategy involves reassembly of split-
dCas9 by photoinducible dimerization domains 
termed Magnets (pMag and nMag) (Fig. 2.2C) in 
response to exposure to blue light (Kawano et al., 
2015; Nihongaki et al., 2015a).
In order to control effector recruitment rather 
than split-(d)Cas9 reconstitution, the heterodimer-
ization partners CRY2 and CIB1 have been used to 
bring together full-length dCas9 and effectors such 
as VP64 or p65 upon blue light irradiation (Koner-
mann et al., 2013; Nihongaki et al., 2015b; Polstein 
and Gersbach, 2015) (Fig. 2.2C). Although the 
light-inducible CRY2–CIB1 pair works well to 
bring together dCas9 and effectors, the use of these 
partners was unsuccessful when applied to reassem-
bly of split-(d)Cas9 (Nihongaki et al., 2015a).
An alternative strategy to control the binding of 
Cas9 to its target sequence relies on intein-mediated 
splicing (Davis et al., 2015; Truong et al., 2015). 
Designs with intein in the reading frame of full-
length Cas9 or fused to both fragments of split-Cas9 
have been used. In both cases, after intein trans-
splicing is induced full-length functional Cas9 is 
obtained (Davis et al., 2015; Truong et al., 2015). 
An other, less common approach, is to use Cas9 
inactive due to caging of lysine residues necessary 
for Cas9 function (Hemphill et al., 2015). Exposure 
to UV light removes the caging group (Riggsbee 
and Deiters, 2010) and recovers an active Cas9 
(Hemphill et al., 2015).
Due to the availability of Cas9 orthologues 
(Chylinski et al., 2014) and redesigned synthetic 
Cas9 proteins (Kleinstiver et al., 2015; Hirano et al., 
2016) with different PAM recognition sequences 
(Table 2.1), combinations of multiple dCas9 
orthologues and matching sgRNAs can be used 
in parallel to perform distinct activities. In E. coli 
two orthologues have been used to simultaneously 
cleave viral dsDNA and repress a reporter gene 
via transcriptional blockage (using a nuclease-
active SpyCas9 and a deactivated NmCas9 protein 
respectively) (Esvelt et al., 2013). In this study it 
was established that N. meningitidis, S. thermophi-
lus CRISPR1 and S. pyogenes Cas9 function fully 
orthogonal to one another in E. coli as well as in 
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human cells, allowing for targeting distinct and 
non-overlapping sets of sequences within the same 
cell (Esvelt et al., 2013). The three catalytically 
deactivated Cas9 orthologues from the same three 
species have been used to label distinct chromo-
somal loci in live human cells (Ma et al., 2015).
Applications of the dCas9 tool
Targetable DNA-binding proteins with additional 
activity in epigenetic editing and/or gene expres-
sion modulation can be divided in two categories 
based on the nature of the effector: (i) targeted 
transcription factors (TTFs) and (ii) targeted 
epigenetic modifiers (TEMs) (Table 2.2). Effectors 
used in TTFs are (derivatives of) natural abun-
dant and potent transcription factors that affect 
gene expression, but also often have indirect and 
multilateral effects on the states of the epigenome 
through recruitment of (multiple) effector partners. 
Commonly used effectors are herpes simplex viral 
protein 16, VP16 (Wang et al., 2000; Memedula and 
Belmont, 2003) – better known in tetrameric form 
as VP64 (Beerli et al., 1998) – and p65, a subunit 
of the human NF-κB transcription factor (Schmitz 
and Baeuerle, 1991). Both effectors exhibit complex 
mechanisms of transactivation via recruitment of 
secondary transcription factors (Mittler et al., 2003; 
Table 2.1 Overview of Cas9 orthologues and synthetic redesigned Cas9s. Orthologues indicated with a + have 
been used as dCas9 systems. Abbreviations: N = any base; D = A, G or T; Y = C or T; R = G or A; W = A or T. Note: 
PAM sequences shown here are consensus sequences derived from sequence logos (i.e. nucleotide frequency 
plots) retrieved from bioinformatics analyses and/or cleavage assays using libraries of putative PAMs
Cas9 Origin 5′-PAM-3′ References
BlCas9 Brevibacillus laterosporus NNNNCNDD Karvelis et al., 2015
CdCas9 Corynebacterium diphtheriae NGG Ran et al., 2015
CjCas9 Campylobacter jejuni NNNNACA Fonfara et al., 2014
ClCas9 Campylobacter lari NNGGG Ran et al., 2015
FnCas9 Francisella novicida NG Fonfara et al., 2014
FnCas9RHA Mutant E1369R/E1449H/R1556A YG Hirano et al., 2016
LiCas9 Listeria innocua NGG Esvelt et al., 2013
NcCas9 Neisseria cinerea NNNNGTA Ran et al., 2015
NmCas9+ Neisseria meningitidis NNNNGATT Hou et al., 2013; Zhang et al., 2013
PlCas9 Parvibaculum lavamentivorans NNNCAT Ran et al., 2015
PmCas9 Pasteurella multocida GNNNCNNA Fonfara et al., 2014
SaCas9 Staphylococcus aureus NNGRR(T) Kleinstiver et al., 2015; Ran et al., 
2015
SmCas9 Streptococcus mutans NGG Fonfara et al., 2014; van der Ploeg, 
2009
SpaCas9 Streptococcus pasteurianus NNGTGA Ran et al., 2015
SpyCas9+ Streptococcus pyogenes NGG Jinek et al., 2012
SpyCas9EQR Mutant D1135E/R1335Q/T1337R NGG (increased 
specificity)
Kleinstiver et al., 2015
SpyCas9QQR1 Mutant G1218R/N1286Q/I1331F/D1332K/
R1333Q/R1335Q/T1337R
NAAG Anders et al., 2016
SpyCas9VQR Mutant D1135V/R1335Q/T1337R NGAN Kleinstiver et al., 2015
SpyCas9VRER Mutant D1135V/G1218R/R1335E/T1337R NGCG Kleinstiver et al., 2015
St1Cas9+ Streptococcus thermophilus** (CRISPR 1) NNARAAW Deveau et al., 2008; Fonfara et al., 
2014; Horvath et al., 2008
St3Cas9 Streptococcus thermophilus* (CRISPR 3) NGG(NG) Fonfara et al., 2014; Horvath et al., 
2008
TdCas9+ Treponema denticola NAAAAN Esvelt et al., 2013
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van Essen et al., 2009). As transcription repressor 
the Krüppel-associated box (KRAB), a domain 
found in numerous mammalian repressors, is com-
monly used. Together with recruited co-repressor 
KAP1, KRAB attracts a variety of epigenetic 
modifiers and chromatin remodelling proteins to 
induce heterochromatin and block transcription 
(Groner et al., 2010). TEMs are designed based 
Table 2.2 An overview of effectors used in dCas9 systems
Direct fusion
Indirect recruitment
ReferencesscRNA SunTag Light-induced
Targeted transcription factors (TTFs)
Activating VP64 Chavez et al., 2015; Farzadfard et al., 2013; 
Gao et al., 2014; Gilbert et al., 2013; Hilton 
et al., 2015; Hu et al., 2014; Kearns et al., 
2014; Maeder et al., 2013b; Mali et al., 
2013b; Perez-Pinera et al., 2013; Polstein 
and Gersbach, 2015; Zetsche et al., 2015a
VP64 Cheng et al., 2016; Mali et al., 2013b; 
Zalatan et al., 2015
VP64 Gilbert et al., 2014; Tanenbaum et al., 2014
VP64 Konermann et al., 2013; Nihongaki et al., 
2015b; Polstein and Gersbach, 2015
VP48 Cheng et al., 2013
VP120 Cheng et al., 2013; Gao et al., 2014
VP64 VP64 or p65 
+/- HSF1 or 
MyoD1
Konermann et al., 2015
p65 Gilbert et al., 2013
p65 p65 or VP64 Konermann et al., 2015
p65 Nihongaki et al., 2015b
P65-HSF1 Cheng et al., 2016
P65-HSF1 Cheng et al., 2016
VP64-p65-Rta Chavez et al., 2015
Repressing KRAB Farzadfard et al., 2013; Gao et al., 2014; 
Gilbert et al., 2013; Hu et al., 2014; Kearns 
et al., 2014, 2015; Lawhorn et al., 2014; 
Thakore et al., 2015
KRAB Cheng et al., 2016; Zalatan et al., 2015
SID4x Konermann et al., 2013
Mxi1 Gilbert et al., 2013
Targeted epigenetic modifiers (TEMs)
Histone 
acetylation
p300  Hilton et al., 2015
CBP Cheng et al., 2016
CBP Cheng et al., 2016
Histone 
demethylation
LSD1 Kearns et al., 2015
DNA 
methylation
DNMT3A McDonald et al., 2016; Vojta et al., 2016
DNA 
demethylation
TET1 TET1 Xu et al., 2016
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on epigenetic effectors, i.e. (derivatives of or active 
domains of) enzymes that catalyse the transfer or 
removal of epigenetic modifications. Epigenetic 
effectors that have been used as TEMs are DNA 
methyltransferase 3A (DMT3A) (McDonald et al., 
2016; Vojta et al., 2016), TET1 5mC-hydroxylase 
(Maeder et al., 2013a; Xu et al., 2016), LSD1 
histone demethylase (Mendenhall et al., 2013; 
Kearns et al., 2015) and the p300 and CBP histone 
acetyltransferases (Hilton et al., 2015; Cheng et al., 
2016). Below, we discuss applications of epigenetic 
editing by TEMs or indirect modulation by TTFs 
using dCas9 as DNA-binding platform.
Manipulating the epigenome and 
gene expression using TEMs and 
TTFs
So far only a few studies have been published 
reporting the use of dCas9 fusions for epigenome 
editing and manipulating gene expression. The 
catalytic histone acetyltransferase (HAT) core 
domain p300 has been used to catalyse acetylation 
of histones in human HEK293T cells (Hilton et al., 
2015). Targeting dCas9–p300 fusions to promoter 
regions or proximal or distant enhancers caused 
activation of gene expression. Increased expres-
sion upon enhancer-targeting was concomitant 
with enrichment in H3K27ac at the correspond-
ing genomic target sites (Hilton et al., 2015). In 
most cases the same genes could be transactivated 
by dCas9-VP64 when targeted at promoters. To 
achieve transactivation both effectors can thus 
be used. The two effectors behave somewhat 
differently in terms of their impact on histone acet-
ylation state, as p300 directly catalyses H3K27ac 
(Ogryzko et al., 1996; Delvecchio et al., 2013), 
whereas VP64 recruits subsequent transactivation 
components, amongst which is p300 (Memedula 
and Belmont, 2003). Also the histone acetyl-
transferase domain of the CREB-binding protein 
has been fused to dCas9 (dCas9-CBPHAT) and 
has been used to catalyse locus-specific acetylation 
of histones (Cheng et al., 2016). dCas9-CBPHAT 
was targeted using the Casilio (CRISPR/Cas9-
Pumilio) system, which harbours an scRNA 
containing multiple PUF binding sites (PBS), to 
recruit additional CBPHAT domains via fusions 
with Pumilio/FBF (PUF) RNA-binding domains. 
Similar to dCas9-p300, targeting dCas9-CBPHAT 
to promoters or proximal and distal enhancer 
caused increased expression of the target genes 
(Cheng et al., 2016).
dCas9 has also been used to introduce DNA 
methylation by targeting the catalytic domain of the 
de novo DNA methyltransferase 3A (DNMT3A) to 
specific loci. dCas9-DNMT3A has been used to 
methylate cytosines around the transcription start 
site (TSS) of human and mice genes (McDonald 
et al., 2016; Vojta et al., 2016). Using this strategy, 
the methylation status of the CpG island spanning 
the TSS of the tumour-suppressor gene CDKN2A 
increased by 20%, resulting in 40% reduction in 
CDKN2A mRNA levels (McDonald et al., 2016). 
Targeting the unmethylated promoter regions of 
the BACH or IL6ST genes increased CpG methyla-
tion by 50% and reduced expression 2-fold (Vojta et 
al., 2016). However, this increase in methylation is 
not the only cause of reduced expression; catalyti-
cally inactive DNMT3A also induced repression, 
attributed to steric hindrance of the transcription 
machinery (McDonald et al., 2016; Vojta et al., 
2016). In contrast, when dCas9-DNMT3A was 
targeted to a CpG island 100–400 bp downstream 
of the TSS, resulting in an increase of 20–35% 
methylation of CpG residues, no significant change 
in CDKN2A mRNA expression was observed 
(McDonald et al., 2016). Upon targeting dCas9-
DNMT3A to the unmethylated Cdkn1a gene in 
mouse myeloid progenitor cells resulting in Cdkn1a 
repression, proliferation was enhanced. In these 
studies dCas9 was as effective in introducing DNA 
methylation as ZFP- or TALE-based DNMT3A 
systems. The highest efficiency of methylation of 
targeted CpG residues was obtained when target 
sites are bracketed by inwardly directed sgRNAs 
(i.e. target CpGs are downstream of the PAM) and 
within ~50 bp of the sgRNA binding site (McDon-
ald et al., 2016; Vojta et al., 2016).
Recently the catalytic domain of TET1 was 
used to induce demethylation of DNA (Xu et al., 
2016). In this study the catalytic domain of TET1 
was fused to dCas9 and two additional copies of the 
same effector were directed to the target location 
via two MS2 aptamers integrated in the sgRNA 
design (Xu et al., 2016). Transiently delivered 
scRNA/dCas9-TET1 induced demethylation of 
the targeted RANKL gene, a gene silenced through 
hypermethylation in HEK-293FT cells, and about 
2-fold increased RANKL mRNA levels. Stable 
expression of the system yielded stronger effects: 
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10- to 20-fold transactivation (Xu et al., 2016). To 
demonstrate the generic applicability of this epig-
enome editing strategy, expression of MAGEB2 and 
MMP2, which are both silenced by hypermethyla-
tion in HeLa cells, was shown to be up-regulated by 
targeted demethylation. Interestingly, combin-
ing multiple sgRNAs that target distinct sites in 
the RANKL and MAGE genes does not result in 
significant additive or synergistic increase in trans-
activation (Xu et al., 2016). A similar non-additive 
effect in transactivation was observed for dCas9-
p300 targeted to multiple adjacent sites to induce 
histone acetylation (Hilton et al., 2015).
Characterizing known or discovering 
new regulatory elements in the 
genome
Large-scale mapping of the human epigenome 
and chromatin states reveals vast numbers of 
putative regulatory elements (ENCODE Project 
Consortium, 2012; Thurman et al., 2012; Road-
maps Epigenomics Consortium et al., 2015). The 
validation and characterization of these elements 
benefits from the use of targetable epigenetic effec-
tors to establish the functions of these regions in 
the genome.
In order to establish whether dCas9-LSD1 can 
be used to investigate enhancer function, the fusion 
protein has been targeted at well-characterized 
and putative enhancers in mouse embryonic stem 
cells. Before the introduction of dCas9, TALE–
LSD1 fusion proteins had been already used to 
target endogenous candidate regulatory elements 
enriched for H3K4me2 and H3K27ac (Menden-
hall et al., 2013). These studies established that at 
a subset of putative enhancers the epigenetic state 
was altered following LSD1 targeting, permitting 
identification of the down-regulated target genes 
(Mendenhall et al., 2013). Targeting of LSD1 
to eight putative pluripotency-specific enhanc-
ers using dCas9 resulted in the discovery of four 
enhancers regulating the expression of genes 
critical in maintaining embryonic state (Kearns 
et al., 2015). Chromosome conformation cap-
ture (3C) confirmed that the target gene was not 
down-regulated through enhancer–promoter 
loop disturbance of dCas9-LSD1 binding per 
se. A reduction in H3K4me2 and H3K27ac was 
observed around the sgRNA-dCas9-LSD1 target 
site in the identified Tbx3-enhancer. In contrast, 
dCas9-KRAB targeted to the same site in the Tbx3-
enhancer resulted in a reduction of H3K27ac and 
an increase of H3K27me3 and H3K9me3 at the 
Tbx3 proximal promoter region. However, neither 
dCas9-KRAB nor dCas9-LSD1 was able to increase 
the level of the repressive marks H3K27me3 and 
H3K9me3 at the Tbx3-enhancer region. In a differ-
ent study, in which the KRAB domain was targeted 
at the HS2 enhancer in the globin locus control 
region (LCR) in human K562 cells, H3K9me3 
marks were effectively introduced at the target 
enhancer region (Thakore et al., 2015). The intro-
duction of these repressive marks was concurrent 
with decreased chromatin accessibility at the target 
site in the enhancer as well as in several other parts 
of the LCR (Thakore et al., 2015). These findings 
suggest pleiotropic effects of dCas9-KRAB at the 
targeted enhancer–promoter loop or as yet unchar-
acterized downstream mechanisms of chromatin 
reorganization.
Genome-wide forward screening
Using libraries of targeted DNA-binding platforms 
fused to effectors the epigenetic states and/or 
expression levels of genes can be altered to study 
their impact on selected downstream processes or 
phenotypes in genome-wide forward screens. Such 
screening applications gain momentum due to 
expanding number of high-resolution techniques 
to measure epigenetic landscapes and chromatin 
states (Zentner and Henikoff, 2014; Ramani et al., 
2016), including the introduction of novel meth-
ods for mapping epigenetic modifications in the 
genomes of single cells (Angermueller et al., 2016; 
Song et al., 2016).
The application of dCas9 in forward screening 
using targeted transcription factors (TTFs) was 
shown to permit highly specific genome-scale 
transcription modulation (Gilbert et al., 2014; 
Konermann et al., 2015). Using combinations of 10 
sgRNAs per gene, tiling −50 to +300 bp for repres-
sion (CRISPRi) or −400 to −50 bp for activation 
(CRISPRa) around the TSS to target nearly 1600 
protein-encoding genes, human K562 cells were 
screened for growth phenotypes. In this study 
transcription was repressed using dCas9-KRAB 
and activated using dCas9-SunTag recruiting scFv–
VP64 fusions (Gilbert et al., 2014). In a second 
screen, known as well as novel complexes and 
pathways involved in the response to a chimeric 
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cholera–diphtheria toxin were identified (Gilbert 
et al., 2014). Using next-generation sequencing, 
sgRNAs guiding the dCas9-effectors could after-
wards be identified to determine the genomic locus 
responsible for the screened phenotypic character-
istics (Gilbert et al., 2014; Konermann et al., 2015). 
A crucial aspect of screening studies using dCas9–
effector fusions is that due to improved sgRNA 
design and more effective dCas9 design strategies, 
one dCas9 recruited by a single sgRNA now suf-
fices in modulating a specific locus (Konermann et 
al., 2015).
Current hurdles in application of 
dCas9
dCas9 has been shown to exhibit off-target binding 
at genome-wide scale (Kuscu et al., 2014; Tsai et 
al., 2015). Studies on target specificity have mainly 
been done on Cas9 (Fu et al., 2014; Slaymaker et al., 
2016; Kleinstiver et al., 2016); these findings can be 
extrapolated to dCas9 and dCas9-based effectors. 
The ability of the Cas9–sgRNA complex to local-
ize and bind at a target sequence could be altered 
by genome accessibility as a consequence of local 
chromatin environment (Knight et al., 2015) or 
binding of endogenous proteins such as transcrip-
tion factors (Hilton et al., 2015). Taking that notion 
into account target sites can be selected based on 
information regarding genome-bound proteins (e.g. 
using DNase-seq) (Maeder et al., 2013b; Kearns et 
al., 2014; Thakore et al., 2015). Alternatively, DNA 
accessibility and off-target binding are determined 
ad hoc for every application. Off-target binding is 
related to flexibility in PAM sequence recognition 
and permitted mismatches in the PAM-distal part 
of the sgRNA (Kim et al., 2015; Ran et al., 2015; 
Tsai et al., 2015; Wang et al., 2015b; Leenay et al., 
2016). Efforts to reduce off-target binding include 
rational redesign of Cas9 for higher PAM specificity 
(Kleinstiver et al., 2015), reduction of non-specific 
charge interactions between Cas9 and non-target 
DNA strand (Slaymaker et al., 2016) or hydrogen 
bonding between Cas9 and the backbones of the 
target DNA strand and the sgRNA (Kleinstiver et 
al., 2016), as well as use of truncated sgRNAs (Fu 
et al., 2014). Although many of these strategies lead 
to a reduction of the DNA binding affinity of Cas9 
or its activity, these efforts have contributed signifi-
cantly to overcoming Cas9 off-target binding.
Another issue for applications of dCas9 is 
its size. The coding sequence of the widely used 
SpyCas9 is around 4.2 kb, which is compatible with 
the ~4.5 kb maximum accommodated in common 
viral vectors used for delivery in mammalian cells. 
However, such a long dCas9 coding sequence does 
not leave ‘space’ for sgRNA sequences and regula-
tory elements to be co-delivered. This limits the 
application of some more complex design strate-
gies such as extending the sgRNA with aptamers, 
adding effector domains to dCas9 or using pools 
of multiple sgRNAs. The relatively small Cas9 
orthologue from Staphylococcus aureus (SaCas9) 
is 3.2 kb in size (Friedland et al., 2015; Ran et al., 
2015). The use of such small orthologues reduces 
the size problem with no drawbacks on activity, 
as observed for a truncated SpyCas9 derivative in 
which a less-conserved, non-interacting portion of 
the recognition lobe had been removed (Nishimasu 
et al., 2014). The split-dCas9 system also provides a 
solution to the size problem, but it requires two vec-
tors for delivery (Truong et al., 2015). Alternatively, 
cells stably expressing dCas9-effector proteins can 
be complemented by delivery of sgRNA, but stable 
expression is difficult to achieve when using primary 
cells or multicellular organisms. Another option is 
dCas9 delivery using in vitro assembled sgRNA-
(d)Cas9 ribonucleoproteins (RNPs), an approach 
which was successful for dCas9-VP64 (Zuris et al., 
2015) and Cas9 genome editing applications (Cho 
et al., 2013b; Kim et al., 2014; Ramakrishna et al., 
2014; Sun et al., 2015; Zuris et al., 2015; D’Astolfo 
et al., 2015). Finally, a potential hurdle for imple-
mentation in living organisms is the fact that the (d)
Cas9 protein elicits an immunogenic responses due 
to its exogenous origin (Wang et al., 2015a). Future 
dedicated studies will need to clarify the extent of 
this issue for possible clinical applications.
Conclusions and future 
perspectives
The importance of the epigenome is becoming 
increasingly clear in the light of developmental 
processes, cell differentiation status and diseases. In 
an attempt to draw causal relations rather than cor-
relations to understand and control the interplay 
between the epigenome, chromatin structure and 
gene expression levels, targetable DNA-binding 
proteins have shown to be of great value. dCas9 has a 
more robust yet readily adjustable DNA-recognition 
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mechanism compared to ZFPs and TALEs; it has 
proven to be a flexible tool in recruiting effector 
domains to targeted DNA-sequences, in particular 
due to the numerous options arising from expand-
ing the sgRNA even up to 5 kb long autonomous 
functional RNAs (Shechner et al., 2015). The full 
value of dCas9 in the field of epigenetics has yet to 
be revealed with more functional studies at local 
scales and genome-wide level, providing detailed 
causal relations between epigenetic modifications, 
chromatin structure and gene expression. Future 
application in translational sciences such as medi-
cine, synthetic biology or biotechnology, rely on 
advances in overcoming final hurdles provided by 
delivery problems due to its size, possible immuno-
genic response and off-target effects.
Alternatives for dCas9 emerge from the dis-
covery and characterization of novel and known 
CRISPR systems involving protein complexes with 
different DNA-recognition mechanisms or differ-
ent dimensions. Possible alternatives have recently 
become available in the form of the relatively small 
Cpf1 (~3.9 kb) (Zetsche et al., 2015a; Yamano et 
al., 2016), the C2c1 and C2c3 systems (Shmakov 
et al., 2015) or even the multiprotein Cascade 
complex from the abundant Type I-E system native 
to E. coli K-12 (Luo et al., 2015). These and future 
related systems add to a comprehensive CRISPR-
based toolbox with distinct and orthogonal guiding 
crRNA, protospacer- or PAM-recognition, which 
is destined to occupy a permanent and prominent 
place in molecular biology.
Glossary
VP64: A strong transcriptional activation domain 
that recruits a variety of transcription factors and 
chromatin remodelling factors (Cress and Triezen-
berg, 1991). Tetrameric fusion of the acidic domain 
of herpes simplex viral protein 16 (VP16) (Beerli et 
al., 1998).
p65: The 65 kDa subunit of the NF-κB transcrip-
tion factor (Schmitz and Baeuerle, 1991). Often 
the principal transactivation domain (TA1) is used 
as activation domain (p65AD).
KRAB: Krüppel-associated box (KRAB) is 
a common repression domain in eukaryotic 
transcription factors (Margolin et al., 1994). It asso-
ciates with KAP1, which forms a scaffold to recruit 
several proteins involved in inducing and spreading 
of heterochromatin over large distances (Groner et 
al., 2010).
p300: Human transcriptional regulatory protein 
able to acetylate histone 3 at lysine residue 27 
(Ogryzko et al., 1996), a signal for active transcrip-
tion. Often the isolated catalytic core of p300, 
containing the histone acetyltransferase (HAT) 
domain, is used as effector.
CBP: The CREB-binding protein (CBP) is able to 
bind many different transcription factors, acting 
as scaffold to co-activate transcription (Chan and 
La Thangue, 2001). Additionally, it has a histone 
acetyl transferase (HAT) domain, which can be 
used as epigenetic effector to acetylate lysine resi-
dues in histones.
LSD1: Lysine-specific demethylase 1 (LSD1) 
demethylates histone 3 at lysine residues 4 and 9, 
leading to silencing of enhancers (Shi et al., 2004). 
LSD1 functionally interacts with other chromatin-
modifying enzymes, including histone deacetylases 
that remove acetyl groups from histone 3 at lysine 
residue 27 (Lee et al., 2006).
DNMT3A: DNA methyltransferase 3A 
(DNMT3A) catalyses de novo DNA methylation 
as well as methylation of hemimethylated DNA, 
preferentially at CpG sites (Okano et al., 1998; Oka 
et al., 2006). Methylated CpGs in promoters are 
associated with silenced transcription.
TET1: Ten-eleven translocation (TET) 
methylcytosine dioxygenase (TET1) is able 
to oxidate 5-methyl cytosines (5mC) to 
5-hydroxymethylcytosines (5hmC), a step in the 
active removal of 5mC (Tahiliani et al., 2009; Xu et 
al., 2011). At promoters, this oxidation and removal 
is associated with activation of silenced genes.
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